tiprankstipranks
Advertisement
Advertisement

CH:AB3A Stock Latest News

Sarepta Shareholders Approve 2026 Equity and ESPP Plans
Company AnnouncementsSarepta Shareholders Approve 2026 Equity and ESPP Plans
24d ago
8K
SRPT
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe Fly
Acting FDA head vows to block political interference, Endpoint News says
24d ago
AZN
BMY
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
26d ago
AZN
BMY
Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
PremiumRatings
Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
1M ago
SRPT
Sarepta price target lowered to $19 from $20 at Evercore ISI
PremiumThe Fly
Sarepta price target lowered to $19 from $20 at Evercore ISI
1M ago
SRPT
FDA Commissioner Marty Makary resigns
PremiumThe FlyFDA Commissioner Marty Makary resigns
2M ago
AZN
BMY
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
Premium
The Fly
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
2M ago
AZN
BMY
Trump Trade: U.S. plans AI security order without required model tests
Premium
The Fly
Trump Trade: U.S. plans AI security order without required model tests
2M ago
DYN
RNA
Trump approves plan to fire FDA head Marty Makary, CBS reports
PremiumThe Fly
Trump approves plan to fire FDA head Marty Makary, CBS reports
2M ago
DYN
RNA
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
PremiumRatings
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
2M ago
SRPT
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
PremiumRatings
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
2M ago
SRPT
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
PremiumRatings
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
2M ago
SRPT
Sarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
PremiumRatingsSarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
2M ago
SRPT
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
Premium
Ratings
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
2M ago
SRPT
Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year
Premium
The Fly
Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year
2M ago
SRPT
Sarepta Therapeutics Signals Profits Amid Alevitus Tests
PremiumCompany Announcements
Sarepta Therapeutics Signals Profits Amid Alevitus Tests
2M ago
SRPT
SRPT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SRPT Upcoming Earnings Report: What to Expect?
2M ago
SRPT
Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
PremiumThe Fly
Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
2M ago
BA
BE
Roche decision could hurt Sarepta in U.S., says H.C. Wainwright
PremiumThe Fly
Roche decision could hurt Sarepta in U.S., says H.C. Wainwright
2M ago
CHRO
SRPT
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
PremiumThe FlyHemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
3M ago
DYN
RNA
Sarepta price target raised to $19 from $18 at RBC Capital
Premium
The Fly
Sarepta price target raised to $19 from $18 at RBC Capital
3M ago
SRPT
Deutsche ups Sarepta target, says 35% stock rally overdone
Premium
The Fly
Deutsche ups Sarepta target, says 35% stock rally overdone
3M ago
SRPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >